COVID-19 Dominates Top 10 UArizona Health Sciences News Stories of 2020

Antibody tests, groundbreaking research and community outreach are a few of the ways the University of Arizona Health Sciences met the test of a pandemic.

COVID-19, social distancing, masks, antibody tests and the quest for a vaccine dominated the media this year, and University of Arizona Health Sciences researchers contributed to the global pandemic response in myriad ways.

From research to clinical trials and public outreach, UArizona Health Sciences faculty, physicians, scientists, staff and students made their mark during the largest public health crisis in a century. Not surprisingly, COVID-19 was a dominant theme among more than 225 Health Sciences news items posted in 2020.

Here are the Top 10 UArizona Health Sciences releases of the year:

No. 1

UArizona Health Sciences Study Shows SARS-CoV-2 Antibodies Provide Lasting Immunity

Researchers in the UArizona College of Medicine – Tucson’s Department of Immunobiology led a study that showed antibodies for SARS-CoV-2, the virus that causes COVID-19, persist for at least seven months. “We clearly see high-quality antibodies still being produced five to seven months after SARS-CoV-2 infection,” said Deepta Bhattacharya, PhD, an associate professor. Dr. Bhattacharya and Janko Nikolich-Žugich, MD, PhD, professor and head of the Department of Immunobiology, led the research team. (Oct. 12)

No. 2

Pain Relief Caused by SARS-CoV-2 Infection May Help Explain COVID-19 Spread

Research conducted in the College of Medicine – Tucson’s Department of Pharmacology found that the SARS-CoV-2 virus causes pain relief when it binds to the receptor neuropilin-1. The study offers a possible explanation for the unrelenting spread of COVID-19. Based on this study, Professor Rajesh Khanna, PhD, who is affiliated with the UArizona Comprehensive Pain and Addiction Center, will be examining neuropilin as a new target for non-opioid pain relief. (Oct. 1)

No. 3

UArizona, State of Arizona Expand Eligibility for COVID-19 Antibody Testing in Concert with $7.7M Study to Better Understand Immunity

A partnership between the UArizona and the state expanded eligibility for antibody testing to essential workers. The antibody test, developed by researchers at UArizona Health Sciences, determines who has been exposed to and developed an immune response against COVID-19. It was first offered to health care workers and first responders and later became available to the general public. (July 22)

No. 4

UArizona Medical Student Effort to Distribute COVID-19 Awareness Posters in Spanish Gains Supporters Near and Far

Four College of Medicine – Tucson students led a Spanish-language awareness campaign for social distancing, masking and other hygiene measures to retard the spread of COVID-19. “I was talking to classmates later about still seeing a lot of non-compliance or lack of social distancing in grocery stores, Walmart’s and places like that,” said Cazandra Zaragoza, MD, who was a fourth-year medical student at the time. “We realized there really weren't any posters and things in Spanish and, if there are, they have a lot of text and it's not very visual. It's not very appealing.” (May 13)

No. 5

UArizona College of Medicine – Tucson Students Given Option for Early Graduation in Response to COVID-19 Pandemic and

University of Arizona College of Medicine – Phoenix Will Allow Fourth-Year Students to Graduate Early

Senior medical students at the College of Medicine – Tucson and UArizona College of Medicine – Phoenix were given the option to graduate early to begin their residency rotations and join the fight against COVID-19. “Given the extraordinary times in which we find ourselves, and rapidly growing burden the pandemic is placing on our health care system, we stand in admiration of our students who wish to pursue this option,” said College of Medicine – Phoenix Dean Guy Reed, MD. (March 30)

No. 6

Green Light Therapy Shown to Reduce Migraine Frequency, Intensity

The first clinical study to evaluate green light exposure as a therapy for people with chronic migraine resulted in about a 60% reduction in the pain intensity of the headache phase and number of days per month people experienced migraine headaches. Researchers from the College of Medicine – Tucson said green light therapy, which has no associated side effects, was also associated with an improved quality of life. (Sept. 9)

No. 7

UArizona Partners with State to Provide COVID-19 Antibody Tests

With $3.5 million in funding from the state, the UArizona moved ahead with plans to produce blood tests to detect COVID-19 antibodies for Arizona’s front-line workforce of about 250,000 people. University of Arizona President Robert C. Robbins, MD, announced the university also intended to test all of its 45,000 students and 15,000 faculty and staff. (April 14)

No. 8

UArizona Poison Center Warns of Toxic Alcohol Poisonings from Contaminated Hand Sanitizer

A UArizona College of Pharmacy advisory from the Arizona Poison and Drug Information Center reported a handful of hospitalizations in Northern Arizona due to the ingestion of what was believed to be homemade hand sanitizer containing methanol. Methanol is a type of alcohol used to create fuel, solvents and antifreeze. The colorless liquid is volatile, flammable and – unlike ethanol – poisonous when consumed. (June 24)

No. 9

UArizona Launches Two-Way Texting System to Gather and Provide Critical COVID-19 Health Data

A team led by researchers in the UArizona Mel and Enid Zuckerman College of Public Health launched AZCOVIDTXT, a two-way texting system to gather and provide valuable information to track the COVID-19 pandemic in Arizona and identify areas where more resources may be needed. The free service allows people to voluntarily report household members’ health statuses, give and get feedback, and learn about available resources and services, research opportunities and coping methods and tools. (April 20)

No. 10

Personalized Cancer Vaccine Clinical Trial to Expand Following Promising Early Results

A UArizona Cancer Center phase 1 clinical trial sponsored by Moderna Inc. investigated the safety and effectiveness of a personalized cancer vaccine in combination with immunotherapy drug Pembrolizumab. The study reported a 50% response rate for patients with head and neck cancer in its preliminary data. (Nov. 9)

Honorable Mention:

# # #

NOTE: Images available upon request.

About the University of Arizona Health Sciences
The University of Arizona Health Sciences is the statewide leader in biomedical research and health professions training. UArizona Health Sciences includes the Colleges of Medicine (Tucson and Phoenix), Nursing, Pharmacy, and the Mel and Enid Zuckerman College of Public Health, with main campus locations in Tucson and the Phoenix Biomedical Campus in downtown Phoenix. From these vantage points, Health Sciences reaches across the state of Arizona, the greater Southwest and around the world to provide next-generation education, research and outreach. A major economic engine, Health Sciences employs nearly 5,000 people, has approximately 4,000 students and 900 faculty members, and garners $200 million in research grants and contracts annually. For more information: uahs.arizona.edu (Follow us: Facebook | Twitter | YouTube | LinkedIn | Instagram).

Release Date: 
12/16/2020
Original Story: